Tests plasma adsorption with clot removal in acute stroke patients
Tests plasma adsorption added to clot removal in adults with large-vessel acute ischemic stroke.
Key facts
- Who runs it
- Yi Yang
- Where
- Changchun, ChinaSee the site
- Trial code
- Registry title
- Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 30 Jun 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Plasma adsorption
- Endovascular Thrombectomy
- Record updated
- 29 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke caused by a blocked large artery at the front of the brain, who have had clot removal (thrombectomy) that reopened the artery. It tests plasma adsorption after the procedure.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Acute ischemic stroke within 12 hours of symptom onset, with a large vessel blocked in the front of the brain (ICA, MCA-M1, MCA-M2, ACA-A1, ACA-A2 or tandem lesion). Stroke severity score (NIHSS) after the procedure must be 6 to 25.
- Earlier treatment
- Must have had endovascular thrombectomy with successful reopening of the vessel (mTICI grade 2b/3). Randomization and the first plasma adsorption must start within 12 hours after the procedure.
Main reasons for not taking part
- Severe brain swelling with midline shift or brain herniation, or bleeding in the brain tissue (parenchymal hemorrhage type 1 or 2) on CT
- History of cancer, autoimmune disease, or treatment with immunosuppressants, hormones or TNF inhibitors
- Currently taking blood thinners, or a serious blood disorder or abnormal clotting tests
- Severe liver or kidney problems, or serious heart disease (NYHA Class III or IV)
- Pregnancy, breastfeeding, or life expectancy under 3 months
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age 18-80 years, male or female
- Diagnosis of acute ischemic stroke within 12 hours of symptom onset, underwent endovascular thrombectomy (EVT) adhering to current guidelines for large vessel occlusion in the anterior circulation (confirmed by DSA as ICA,MCA-M1,MCA-M2,ACA-A1,ACA-A2 occlusion or tandem lesion) and achieve successful recanalization (mTICI grade 2b/3)
- Baseline NIHSS after EVT ≥ 6 and ≤25 points
- Randomization and the first plasma adsorption can be initiated within 12 hours after EVT
- Pre-stroke mRS≤ 2 points
- Patient/legally family members have signed the Informed consent form
Who cannot take part
- Previous history of organic heart disease and NYHA Class III or IV
- Current or past participation in other clinical research, or participation in this study within 3 months prior to admission
- Imaging after EVT indicated malignant brain edema with midline shift or brain herniation and surgical treatment was planned
- Parenchymal hemorrhage type 1, or type 2 confirmed by CT
- Allergic to any ingredient of the plasma separator, the adsorption device, or the piping
- Previous history of malignant tumors, autoimmune diseases or being treated with immunosuppressants, hormones, or tumor necrosis factor inhibitors
- Other conditions that the researchers think make the patient unsuitable for the study
- Contraindications to plasma adsorption, platelet count <60×10\^9/L,white blood cell<4×10\^9/L, uncontrolled hypertension with persistent systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg, uncontrolled hypotension, systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg
- Currently taking anticoagulant(dabigatran, rivaroxiban, warfarin, etc.), previous history of serious hematological system disorders, or abnormal coagulation function (international normalized ratio [INR], activated partial thromboplastin time [APTT], prothrombin time [PT] upper limit of the normal range)
- Severe liver and kidney dysfunction or abnormal laboratory test results(serum aspartate aminotransferase or alanine aminotransferase >3 times the upper limit of normal, serum creatinine>265umol/l(>3mg/dl))
- Pregnancy , lactation or life expectancy of less than 3 months or inability to complete the study for other reasons
- Unwilling to be followed up or poor compliance
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaContact: Yi Yang, MD,PhDNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.
The 2 groups in the trial
- Plasma adsorption+Endovascular ThrombectomyTreatment being tested
Patients are received plasma adsorption and endovascular thrombectomy.Plasma adsorption was initiated after endovascular thrombectomy once daily for 3 days.
Treatment: Plasma adsorption and Endovascular Thrombectomy
- Endovascular ThrombectomyExisting treatment, for comparison
The patients will be treated with endovascular thrombectomy .
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy and Safety of Plasma Adsorption Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial
- Plain-language title
- Tests plasma adsorption with clot removal in acute stroke patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07042490, who can take part
- Record updated
- 29 June 2025